Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities
Journal Title: Advances in Hygiene and Experimental Medicine - Year 2011, Vol 65, Issue 0
Abstract
Melanoma is a tumour derived from melanocytes, cells of neuroectodermal origin. Melanoma treatment represents a challenge to oncologists due to its aggressive course and early and multiple metastases. Surgical excision of lesions is a highly effective intervention, but only in early stages. In contrast, median survival of patients with metastatic melanoma is still below one year. In 2011 the FDA and EMA have approved new drugs, ipilimumab and vemurafenib, that might be a major breakthrough in treating patients with advanced melanoma. However, time is needed to conclude whether they replace dacarbazine, a drug used for over 30 years in the therapy of metastatic melanoma, even if the response rate was only 10–15%. The mechanism of dacarbazine action is not clear but it is probably based on methylation of purine bases in DNA. The low therapeutic efficacy of dacarbazine might be the consequence of rapid removal of DNA lesions by repair systems. A high melanoma chemoresistance is also driven by the extent and nature of alterations in signal transductions in tumour cells. None of the previously conducted trials proved superiority of any treatment modality over monotherapy with dacarbazine. Higher response rates did not correlate with survival benefit, and more intense adverse effects were frequently observed. There are some expectations for targeted therapy and immunotherapy, which have already demonstrated some efficacy in clinical studies. This review aims at providing the current knowledge on dacarbazine and its analogue, temozolomide, including the latest results of clinical studies combining these drugs with other treatment protocols.
Authors and Affiliations
Kamila Koprowska, Małgorzata Czyż
Keywords
Related Articles
- EP ID EP66568
- DOI -
- Views 170
- Downloads 0
Białka w oporności wielolekowej nowotworów
Wielolekooporność definiowana jest jako brak wrażliwości na podawane leki, które nie wykazują strukturalnego podobieństwa, a ponadto mają zróżnicowane molekularne punkty uchwytu. Nowotwory dysponują licznymi mechanizmami...
Antimicrobial/anti-biofilm activity of expired blood platelets and their released products
Introduction. Although platelets are not part of the classical immune system, they have many features that indicate their role in the anti-infective host defense. They come into interactions with microorganisms, which re...
Rola sfingolipidów w układzie pokarmowym
Sfingolipidy odgrywają rolę w licznych fizjologicznych oraz patofizjologicznych procesach, zachodzących w obrębie układu pokarmowego. W błonie komórkowej enterocytów sfingolipidy pełnią funkcję strukturalną, warunkują ab...
MMP-9 directed shRNAs as relevant inhibitors of matrix metalloproteinase 9 activity and signaling
Introduction: The main function of matrix metalloproteinases is the degradation of extracellular matrix components, which is related to changes in the proliferation of cells, their differentiation, motility, and death. M...
Angiotensin (1-7): A new link in the renin-angiotensin-aldosterone system (RAAS)
The discovery of a new angiotensin-converting enzyme (ACE2) and studies of the biological activity of angiotensin (1-7) indicate the complexity of the functioning of the renin-angiotensin-aldosterone system (RAAS). In th...